Oral clarithromycin in COVID-19 of moderate severity: the ACHIEVE open-label trial using concurrent matched comparators

Konstantinos Tsiakos, Antonios Tsakiris, Georgios Tsibris, Pantazis Voutsinas, Periklis Panagopoulos, Maria Kosmidou, Vasileios Petrakis, Areti Gravvani, Theologia Gkavogianni, Eleftherios Klouras, Konstantina Katrini, Panagiotis Koufargyris, Iro Rapti, Athanassios Karageorgos, Emmanouil Vrentzos, Christina Damoulari, Vagia Zarkada, Chrysanthi Sidiropoulou, Sofia Artemi, Androniki Papapostolou, Evangelos Michelakis, Maria Georgiopoulou, Dimitra-Melia Myrodia, Panteleimon Tsiamalos, Konstantinos Syrigos, George Chrysos, Thomas Nitsotolis, Haralampos Milionis, Garyphallia Poulakou, Evangelos J. Giamarellos-Bourboulis
doi: https://doi.org/10.1101/2020.12.22.20248753

Article Information

doi 
https://doi.org/10.1101/2020.12.22.20248753
History 
  • December 26, 2020.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

Author Information

  1. Konstantinos Tsiakos1,
  2. Antonios Tsakiris2,*,
  3. Georgios Tsibris2,*,
  4. Pantazis Voutsinas2,*,
  5. Periklis Panagopoulos3,
  6. Maria Kosmidou4,
  7. Vasileios Petrakis3,
  8. Areti Gravvani1,
  9. Theologia Gkavogianni2,
  10. Eleftherios Klouras4,
  11. Konstantina Katrini2,
  12. Panagiotis Koufargyris2,
  13. Iro Rapti4,
  14. Athanassios Karageorgos2,
  15. Emmanouil Vrentzos2,
  16. Christina Damoulari2,
  17. Vagia Zarkada2,
  18. Chrysanthi Sidiropoulou5,
  19. Sofia Artemi2,
  20. Androniki Papapostolou2,
  21. Evangelos Michelakis2,
  22. Maria Georgiopoulou2,
  23. Dimitra-Melia Myrodia1,
  24. Panteleimon Tsiamalos5,
  25. Konstantinos Syrigos1,
  26. George Chrysos5,
  27. Thomas Nitsotolis1,
  28. Haralampos Milionis4,
  29. Garyphallia Poulakou1 and
  30. Evangelos J. Giamarellos-Bourboulis1,#
  1. 13rd Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, 115 27 Athens, Greece
  2. 24th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, 124 62 Athens, Greece
  3. 32nd Department of Internal Medicine, Democritus University of Thrace, Medical School, 681 00 Alexandroupolis, Greece
  4. 41st Department of Internal Medicine, University of Ioannina, School of Health Sciences, Faculty of Medicine, 455 00 Ioannina, Greece
  5. 52nd Department of Internal Medicine, Tzaneion General Hospital of Piraeus, Greece
  1. ↵#Corresponding Author
    Evangelos J. Giamarellos-Bourboulis, MD, PhD, 4th Department of Internal Medicine, ATTIKON University General Hospital, 1 Rimini Street 124 62 Athens, Greece, Tel: +30 210 58 31 994, Fax: +30 210 53 26 446, E-mail: egiamarel{at}med.uoa.gr

  1. ↵* equal contribution

Back to top
Posted December 26, 2020.
Download PDF

Supplementary Material

Data/Code
Email
Oral clarithromycin in COVID-19 of moderate severity: the ACHIEVE open-label trial using concurrent matched comparators
Konstantinos Tsiakos, Antonios Tsakiris, Georgios Tsibris, Pantazis Voutsinas, Periklis Panagopoulos, Maria Kosmidou, Vasileios Petrakis, Areti Gravvani, Theologia Gkavogianni, Eleftherios Klouras, Konstantina Katrini, Panagiotis Koufargyris, Iro Rapti, Athanassios Karageorgos, Emmanouil Vrentzos, Christina Damoulari, Vagia Zarkada, Chrysanthi Sidiropoulou, Sofia Artemi, Androniki Papapostolou, Evangelos Michelakis, Maria Georgiopoulou, Dimitra-Melia Myrodia, Panteleimon Tsiamalos, Konstantinos Syrigos, George Chrysos, Thomas Nitsotolis, Haralampos Milionis, Garyphallia Poulakou, Evangelos J. Giamarellos-Bourboulis
medRxiv 2020.12.22.20248753; doi: https://doi.org/10.1101/2020.12.22.20248753
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area